Press releaseGlobe Newswire
X4 Pharmaceuticals
XFOR · NASDAQ
$3.02+$0.27 (+9.82%)TodayMarket closed ·
Prev close $2.75
Latest news
- Press releaseGlobe Newswire
X4 Pharmaceuticals Announces Positive Outcome from FDA Type C Meeting
- NewsAvi Kapoor
Airsculpt Technologies, Barrick Mining And Other Big Stocks Moving Lower In Monday’s Pre-Market Session
- Press releaseGlobe Newswire
X4 Pharmaceuticals Reports Second Quarter 2026 Financial Results and Provides Corporate Update
- News
Earnings Scheduled For May 6, 2026
- News
X4 Pharmaceuticals Q1 EPS $(0.16) Beats $(0.20) Estimate, Sales $2.708M Miss $3.200M Estimate
- Press releaseGlobe Newswire
X4 Pharmaceuticals Reports First Quarter 2026 Financial Results and Provides Corporate Update
- Press releaseGlobe Newswire
X4 Pharmaceuticals Announces European Commission Approval of XOLREMDI® (Mavorixafor), the First and Only Authorized Treatment for Patients with WHIM Syndrome in the European Union
- News
12 Health Care Stocks Moving In Tuesday's Intraday Session
- News
12 Health Care Stocks Moving In Tuesday's Pre-Market Session
- Press releaseGlobe Newswire
X4 Pharmaceuticals Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Corporate Update
- News
12 Health Care Stocks Moving In Friday's After-Market Session
- Press releaseGlobe Newswire
X4 Pharmaceuticals Receives Positive Opinion from the EMA CHMP Recommending Approval of Mavorixafor in the EU for WHIM Syndrome
- NewsAvi Kapoor
Dynavax Technologies, Omeros, Agios Pharmaceuticals, Nike And Other Big Stocks Moving Higher On Wednesday
- Press releaseGlobe Newswire
X4 Pharmaceuticals Announces Pricing of $135 Million Underwritten Public Offering
- Press releaseGlobe Newswire
X4 Pharmaceuticals Announces Proposed Underwritten Public Offering
- Press releaseGlobe Newswire
Altimmune Appoints Industry Veteran Christophe Arbet-Engels, M.D., PhD as Chief Medical Officer to Drive Next Phase of Clinical Development of Pemvidutide
- News
12 Health Care Stocks Moving In Tuesday's Intraday Session
- News
12 Health Care Stocks Moving In Monday's After-Market Session
- News
12 Health Care Stocks Moving In Wednesday's Pre-Market Session
- News
12 Health Care Stocks Moving In Tuesday's Intraday Session
- News
12 Health Care Stocks Moving In Tuesday's Pre-Market Session
- Press releaseGlobe Newswire
X4 Pharmaceuticals Reports First Quarter 2025 Financial Results and Provides Corporate Updates
- News
Breaking Down X4 Pharmaceuticals: 4 Analysts Share Their Views
- Press releaseGlobe Newswire
X4 Pharmaceuticals Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Corporate Update
- News
12 Health Care Stocks Moving In Thursday's Pre-Market Session
Information on this page is provided for informational purposes only and is not a recommendation to buy, sell or hold any security. Investing involves risk, including possible loss of principal. Market data is delayed at least 15 minutes and is provided without warranty. Analyst ratings, price targets and company data come from third-party sources. Past performance does not guarantee future results.